HLA antigen as predictive index for the outcome of breast cancer patients with adjuvant immunochemotherapy with PSK

Anticancer Research

Volumn 17, Issue 4 A, 1997, Pages 2815-2818

  Yokoe, Takao ^a,b   Iino, Yuichi ^a   Takei, Hiroyuki ^a   Horiguchi, Jun ^a   Koibuchi, Yukio ^a   Maemura, Michio ^a   Ohwada, Susumu ^a   Morishita, Yasuo ^a  

^a GUNMA UNIVERSITY   (Japan)

^b GUNMA UNIVERSITY   (Japan)

Author keywords

Adjuvant therapy; Breast cancer; HLA; PSK

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; KRESTIN; MITOMYCIN C; PREDNISOLONE;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HLA TYPING; HUMAN; LYMPH NODE METASTASIS; LYMPHOCYTOTOXICITY; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HLA ANTIGENS; HUMANS; IMMUNOTHERAPY; MIDDLE AGED; PROGNOSIS; PROTEOGLYCANS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 0030841010     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Brewerton DA, Hart FD, Nicholls A, Caffrey M, James DC, Sturrock RD: Ankylosing spondylitis and HL-A27. Lancet 1(809): 904-907, 1973.
2. Yokoe T, Ishida T, Ogawa T, Iino Y, Izuo M: Relationship of breast cancer and HLA in Japanese female (in Japanese). Gan-no-Rinsho, 36: 29-33, 1990.
3. Yokoe T, Ishida T, Iino Y, Ogawa T: HLA as a predictor of bilateral breast cancer. Abstr Intl Surgical Week, pp446, 1991.
4. Yokoe T, Ishida T, Iino Y, Sugamata N, Yokota T, Takeo T, Takai Y, Horiguchi J, Ogawa T, Morishita Y: Relationship between HLA and prognosis of breast cancer. Ann Cancer Res Ther 2: 125-126, 1993.
5. Tsukagoshi S, Hashimoto Y, Fujii G, Kobayashi H, Nomoto K, Orita K: Krestin (PSK). Cancer Treat Rev 11: 131-155, 1984.
6. Nakazato H, Koike A, Saji S, Ogawa N, Sakamoto J, for the Study Group of Immunochemotherapy with PSK for Gastric Cancer: Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Lancet 343: 1122-1226, 1994.
7. Iino Y, Yokoe T, Maemura T, Horiguchi J, Takei H, Ohwada S, Morishita Y: Immunochemotherapies versus chemotherapy as adjuvant treatment after curative resection of operable breast cancer. Anticancer Res 15: 2907-2912, 1995.
8. Ogoshi K, Satou H, Isono K, Mitomi T, Endoh M, Sugita M: Immunotherapy for esophageal cancer. A randomized trial in combination with radiotherapy and radiochemothrapy. Cooperative Study Group for Esophageal Cancer in Japan. Am J Clin Oncol 18: 216-222, 1995.
9. Hayakawa K, Mitsuhashi N, Saito Y, Takahashi M, Katano S, Shiojima K, Furuta M, Niibe H: Effect of Krestin (PSK) as adjuvant treatment on the prognosis after radical radiotherapy in patients with non-small cell lung cancer. Anticancer Res 13:1815-1820, 1993.
10. Mitomi T, Tsuchiya S, Iijima N, Aso K, Nishiyama K, Amano T, Takahashi T, Oka H, Murayama N, Oya K, Noto T, Ogawa N: Randomized controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer (in Japanese). J Jpn Soc Cancer Ther 28: 71-78, 1993.
11. Fujii T, Saito K, Matsunaga K, Oguchi Y, Ikuzawa M, Furusho T, Taguchi T: Prolongation of survival period with the biological rsponse modifier PSK in rats bearing N-methyl-N-nitrosourea-induced mammary gland tumors. In Vivo 9: 55-57, 1995.
12. Toi M, Hattori T, Akagi M, Inokuchi K, Orita K, Sugimachi K, Dohi K, Nomura Y, Monden Y, Hamada Y, Morimoto T, Ogawa N: Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer. Cancer, 70: 2475-2483, 1992..
13. Kobayashi H, Matsunaga K, Oguchi Y: Antimetastatic effects of PSK (krestin), a protein-bound polysaccharide obtained from basidiomycetes: An overview. Cancer Epidemiol Biomarkers Prev 4: 275-281, 1995.
14. Noguchi K, Tanimura H, Yamaue H, Tsunoda T, Iwahashi M, Tani M, Mizobata S, Hotta T, Arii K, Tamai M et al: Polysaccharide preparation PSK augments the proliferation and cytotoxicity of tumor-infiltrating lymphcytes in vitro. Anticancer Res 15: 255-258, 1995.
15. Sugimachi K, Maehara Y, Kusumoto T, Okamura T, Korenaga D, Kohnoe S, Baba H, Anai H: In vitro activity to a protein-bound polysaccharide PSK of periphral blood lymphcytes from patients with gastrointestinal cancer. Anticancer Res 15: 2175-2179, 1995.
16. Hirose K, Zachariae CO, Oppenheim JJ, Matsushima K: Induction of gene expression and production of immunomodulating cytokines by PSK in human peripheral blood mononuclear cells. Lymphokine Res, 9: 474-483, 1990.
17. Kanoh T, Matsunaga K, Saito K, Fujii T: Suppression of in vivo tumor-induced angiogenesis by the protein-bound polysaccharide PSK. In Vivo 8: 247-250, 1994.
18. Araya S, Nio Y, Hayashi H, Masaí Y, Tsubono M, Ishigami S, Imamura M: Various plant-derived polysaccharides augment the expression of HLA on Colo 205 human colonie cancer cell line. J Jpn Soc Cancer Ther 29: 1965-1973, 1994.
19. D'Andrea A, Chang C, Franz-Bacon K, McClanahan T, Phillips JH, Lanier LL: Molecular cloning of NKB1. A natural killer cell receptor for HLA-B allotype. J Immunol 155: 2306-2310, 1995.
20. Grumperz JE, Litwin V, Phillips JH, Lanier LL, Parham P: The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. J Exp Med 181: 1133-1144, 1995.
21. Gumperz JE, Valiante NM, Pharham P, Lanier LL, Tyan D: Heterogeneous phenotypes of expression of the NKB1 natural killer cell class I receptor among individuals of different human histocompatibility leukocyte antigens types appear genetically regulated, but not linked to major histocompatibility complex haplotype. J Exp Med 183: 1817-1827, 1996.